PRESSRELEASE Halifax Biomedical Inc. (HBI), en ledande leverantör av mikro- instabilitetsbedömningar genom en mycket noggrann och skyddad bildteknik kallad Digital Stereo Radiography (DSR) och Arcoma AB, en ledande tillverkare av avancerade digitala röntgenprodukter (DR) och högkvalitativa autopositionerande röntgensystem, meddelar att man inleder ett samarbete där utrustning och produkter från Arcoma kommer att integreras i HBIs nya mobile Digital Stereo Radiographic (DSR) suite. Samarbetet medför att HBI får möjlighet att föra ut sin avancerade DSR teknologi till ett flertal sjukhus och kliniker med målsättning att slutföra den kliniska valideringen av denna nya teknologi. Det första mobila DSR systemet till vilket utrustning från Arcoma nu beställts, kommer att vara lokaliserat i nordöstra USA och planeras att återföljas av ytterligare DSR system i framtiden. DSR är en teknik med vilken två röntgenbilder tas samtidigt från olika vinklar och synkroniseras med syfte att generera noggranna 3D mätningar av positionen hos implantat eller ben och deras förflyttningar. Den mobila DSR enheten kommer att fokusera på HBIs applikation för mätning av instabilitet i ryggraden och som mäter rörelser mellan kotor i ländryggen, genom användadet av komplexa algoritmer för bildanalys. Halifax Biomedical valde Arcoma som leverantör baserat på den kliniska användbarheten av Arcomas utrustning samt Arcomas goda kvalitetsrykte. J. Erik Giphart, Ph.D., Chief Technology Officer på Halifax Biomedical säger "Arcoma erbjuder de typer av unika lösningar och den flexibilitet we behöver för att paketera ett avancerat röntgensystem i ett mycket begränsat utrymme. Arcoma tillför även nödvändig applikationskunskap och erfarenhet för att kunna slutföra projektet" "Vi är mycket glada över att få arbeta med teamet från Halifax Biomedical och stolta över att man valt Arcoma som leverantör och partner för det nya mycket innovativa mobila DSR systemet" säger Jonas Salomonson, VD på Arcoma AB. Om HALIFAX BIOMEDICAL, Inc.: Halifax Biomedical Inc. (HBI) är verksamma inom evidensbaserade kliniska mätningar för ortopedi. Bolaget har sitt huvudkontor i Nova Scotia, Kanada och har även verksamhet i Cambridge, MA USA. HBI är en världsledande leverantör av teknologi för mikro-instabilitetsbedömningar som utgår från en mycket noggrann och skyddad stereoradiografisk bildteknik. (HALIFAX exams). HBI fokuserar på två kliniska problem; detektering av implantatlossning vid totala höft- och knäersättningar samt kvantifiering av ryggradens instabilitet hos patienter med kronisk smärta i ryggens nedre delar. För ytterligare information, besök gärna www.halifaxbiomedical.com, eller kontakta: John Simon, COO Email: john.simon@halifaxbiomedical.com Office: (902) 945-2771 Fax: (902) 945-2324 Mailing Address: Halifax Biomedical Inc. 1 Broadway, 14th Floor Cambridge, MA 02142 USA Om ARCOMA AB: Arcoma, med över 40 års samlad erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalité och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 2 000 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på NASDAQ OMX First North. Certified Adviser är Sedermera Fondkommission AB. För ytterligare information, besök gärna www.arcoma-imix.com, eller kontakta: Jonas Salomonson, VD Email: jonas.salomonson@arcoma.se Office: +46 470 70 69 00 Fax: +46 470 70 69 99 Mailing Address: Arcoma AB Annavagen 1 SE-352 46 Växjö Sverige [HUG#1881617]
Arcoma AB : Prestigeorder för Arcoma - HALIFAX Biomedical
Top 10 Most Recent News Articles
Leqembi Pen Revolutionizes Alzheimer's Care in Japan
Innovative Alzheimer's Treatment Hits Japanese Market Just when you think the medical world needs a jolt of innovation, BioArctic rolls out something that could change how Alzheimer's is managed. With their subcutaneous Leqembi Pen, they've just added another feather in their cap, launching in Japan after a successful U.S. introduction. Not just your run-of-the-mill...
Continue Reading
Randi Baptiste Sets a New Standard in Youth Sports
Youth Sports: Revolutionized by Randi Baptiste In an era where youth sports face a minefield of health risks and performance pressures, Randi Baptiste stands out. This isn't just about running around the park—this is about fundamentally transforming how we think about athletic development for young folks. Recognizing Baptiste for his contributions, The Inner Circle...
Continue Reading
Simform's AI Innovations Earns Microsoft Award Nod
Riding the AI Wave with Simform In the chaotic world of AI and tech partnerships, earning recognition from a powerhouse like Microsoft ain't your run-of-the-mill achievement. Simform being recognized as a finalist for the 2026 Microsoft Innovate with Azure AI Apps and Agents Partner of the Year Award is a big deal, not just for them, but as a beacon of inspiration for...
Continue Reading
GAC's Green Push Unveils 3rd Showroom in Casablanca
Pushing Through North Africa's Automotive Shift Well, looks like GAC is showing they're not just dabbling in North Africa—they're planting some sturdy roots in that rocky soil. Opening their third showroom in Casablanca, GAC isn't just settling for sidelines. They're step-in-the-ring serious about carving their name on North African roads. This isn't some skin-deep...
Continue Reading
Adam Foundation's Ramadan Effort to Cut Plastic Waste
Environmental Consciousness: A Call from Antalya Here we go again, folks. Something refreshing is brewing over in Antalya at COP31, where the UK-based Adam Foundation has made a move that resonates beyond the usual hubbub. No smoke and mirrors, just straightforward action aimed at cutting down the wave of plastic waste during Ramadan. This isn't some pie-in-the-sky green...
Continue Reading
FF EAI Robotics Aims for Top Spot in K-12 Tech
FFR's Shot at Robotics Education Dominance You ever feel like a company is throwing everything but the kitchen sink at an opportunity? That's FF EAI Robotics for you—charging ahead with a hefty laundry list of tech ambitions. They've clocked in about $2.3 million in revenue from their newly acquired robotics wing for the first nine months of 2026, showing a 26% gross...
Continue Reading
Rethinking Risk: AI, Cyber, and Ops Convergence
Risk Management's New Frontier Hold onto your hats, folks, because the landscape of risk management is shifting under our feet—and not a minute too soon. With AI adoption skyrocketing, cybersecurity threats piling up like never-ending junk mail, and operational hurdles lurking around every corner, Wipfli's throwing down the gauntlet for business leaders to wise up....
Continue Reading
Implantica's Q3 2026: A Potential Leap Forward?
Implantica Prepares to Unveil Q3 Results We're heading into the home stretch for 2026, and Implantica's about to unveil its third-quarter results. With its presentation scheduled for November 19 at 15:00 CET, this medtech outfit has caught some eyes, especially with their flagship offering, RefluxStop®. Paying attention here might be worthwhile, as this plays into a...
Continue Reading
Squeez and Qentelli Join Forces to Revolutionize Loyalty
A New Era of Loyalty Commerce The winds are changing in the loyalty game, and it's about time someone shook things up. Squeez has teamed up with Qentelli, thanks to a $1 million investment, to kick-start this next wave of commerce. And boy, it's not just about money—it's like combining brains with brawn. Squeez isn't just offering loyalty programs anymore; they're...
Continue Reading
Vipshop Sets 2026 AGM: Shareholders Meet on Dec 8
Blockbuster or Bust: Vipshop's Upcoming AGM Here's the scoop: Vipshop Holdings Limited, with its mammoth operations in China's off-price retail sector, is gearing up for its annual general meeting (AGM) on December 8, 2026. This is where management and stakeholders will hash out everything from strategic pivots to financial health. Forget shareholder votes this...
Continue ReadingTop 5 Most Recently Viewed Articles
Actinium Pharmaceuticals Faces Class Action Lawsuit for Losses
Actinium Pharmaceuticals: A Closer Look at the Lawsuit Recently, a significant class action lawsuit was filed against Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This legal action is vital for investors who have experienced financial losses associated with their investments in Actinium's stock. The lawsuit, initiated by Pomerantz LLP, accuses the company and some of its...
Continue Reading
Uranium Energy Corp Delivers Promising Drill Results at Roughrider
Uranium Energy Corp Unveils Outstanding Drilling Results Uranium Energy Corp (NYSE American: UEC) is thrilled to share the latest findings from its active drilling campaign at the Roughrider Project, which have revealed striking high-grade uranium mineralization. A drill hole positioned 850 meters northeast of the central Roughrider deposit has showcased remarkable...
Continue Reading
TME Pharma Presents Promising Glioblastoma Trial Outcomes
TME Pharma's Progress in Glioblastoma Treatment TME Pharma N.V. is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer. Recently, they announced an important oral presentation at a renowned medical congress, showcasing the encouraging results from the NOX-A12 GLORIA Phase 1/2 trial. This study aims to address glioblastoma, a...
Continue Reading
Life Time Champions Expanding Pickleball Facilities Across U.S.
Life Time Champions Expanding Pickleball Facilities Across U.S. Life Time (NYSE: LTH) proudly marks World Pickleball Day as the sport continues to gain unprecedented popularity across America. With over 750 permanent pickleball courts established within its athletic country clubs, the organization demonstrates its commitment to being at the forefront of this dynamic...
Continue Reading
Edgewise Therapeutics Shares Breakthrough EDG-7500 Results
Edgewise Therapeutics Announces Significant Progress in Hypertrophic Cardiomyopathy Treatment Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a pioneering biopharmaceutical company focused on muscle diseases, has recently disclosed positive outcomes from their Phase 2 CIRRUS-HCM trial studying EDG-7500. This treatment targets hypertrophic cardiomyopathy (HCM), a serious...
Continue Reading